Research programme: immuno-oncology therapeutics - Batu Biologics

Drug Profile

Research programme: immuno-oncology therapeutics - Batu Biologics

Alternative Names: Cancer vaccine - Batu Biologics; DendroVax™; hp91; Immittam™; ImmStem™; ImmXcyte™; Stem cell therapy - Batu Biologics; ValloVax™

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Batu Biologics
  • Class Cancer vaccines; Dendritic cell vaccines; Stem cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cell replacements; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma; Non-small cell lung cancer; Solid tumours
  • Discontinued Septic shock

Most Recent Events

  • 08 Nov 2017 USFDA approves IND application for ValloVax™ in Non-small cell lung cancer
  • 07 Nov 2017 Batu Biologics plans a phase I trial for Non-small stage lung cancer in USA
  • 08 Sep 2017 Discontinued - Preclinical for Septic shock in USA (Parenteral) (Batu Biologics pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top